Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction
Abstract Aims Empagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, was shown to be effective in patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR‐Preserved trial. The present study aims to evaluate the cost‐effectiveness of empagliflozin among Japanese patien...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2024-02-01
|
| Серии: | ESC Heart Failure |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/ehf2.14565 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|